Coumarin derivatives bearing benzoheterocycle moiety: synthesis, cholinesterase inhibitory, and docking simulation study

Document Type : Original Article


1 Department of Medical Chemistry, School of Pharmacy, International Campus, Tehran University of Medical Science, Tehran, Iran

2 Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

3 Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

4 Department of Pharmaceutical Biomaterials and Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran, Iran

5 Nanobiomaterials Group, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran


Objective(s): To investigate the efficiency of a novel series of coumarin derivatives bearing benzoheterocycle moiety as novel cholinesterase inhibitors.
Materials and Methods: Different 7-hydroxycoumarin derivatives were synthesized via Pechmann or Knoevenagel condensation and conjugated to different benzoheterocycle (8-hydroxyquinoline, 2-mercaptobenzoxazole or 2-mercaptobenzimidazole) using dibromoalkanes 3a-m. Final compounds were evaluated against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) by Ellman's method. Kinetic study of AChE inhibition and ligand-protein docking simulation were also carried out for the most potent compound 3b.
Results: Some of the compounds revealed potent and selective activity against AChE. Compound 3b containing the quinoline group showed the best activity with an IC50 value of 8.80 µM against AChE. Kinetic study of AChE inhibition revealed the mixed-type inhibition of the enzyme by compound 3b. Ligand-protein docking simulation also showed that the flexibility of the hydrophobic five carbons linker allows the quinoline ring to form π-π interaction with Trp279 in the PAS.
Conclusion: We suggest these synthesized compounds could become potential leads for AChE inhibition and prevention of AD symptoms.


1. Tang H, Zhao HT, Zhong SM, Wang ZY, Chen ZF, Liang H. Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. Bioorg Med Chem 2012; 22: 2257–2261.
2. Querfurth HW, La Ferla FM. Mechanism of disease Alzheimer'disease. N Engl J Med 2010; 362:329–344.
3. Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C. Tacrine derivatives and alzheimer's disease. Curr Med Chem 2010; 17:1825–1838.
4. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003; 2:539–547.
5. Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res 2009; 6:86–96.
6. Mohammadi-Farani A, Abdi N, Moradi AR, Aliabadi AR. 2-(2-(4-Benzoylpiperazin-1-yl) ethyl)isoindoline-1,3-dione derivatives: Synthesis, docking and acetylcholinesterase inhibitory evaluation as anti-alzheimer agents. Iran J Basic Med Sci 2017; 20:59–66.
7. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004; 50:433–440.
8. (a) McGeer EG, McGeer PL. Clinically tested drugs for Alzheimer's disease. Expert Opin Investig Drugs 2003; 12:1143. (b) Osborn GG, Saunders AV. Current treatments for patients with Alzheimer disease. J Am Osteopath Assoc 2010; 110:16–26.
9. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991; 253:872–879.
10. Chen Y, Sun J, Fang L, Liu M, Peng S, Liao H, et al. Tacrine–ferulic acid–nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl-and butyrylcholinesterase inhibitors. J Med Chem 2012; 55:4309–4321.
11. Shanks M, Kivipelto M, Bullock R, Lane R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr Med Res Opin 2009; 25:2439–2446.
12. Lee SJ, Lee US, Kim WJ, Moon SK. Inhibitory effect of esculetin on migration, invasion and matrix metalloproteinase-9 expression in TNF-α-induced vascular smooth muscle cells. Mol Med Rep 2011; 4:337.
13. Huang XY, Shan ZJ, Zhai HL, Su L, Zhang XY. Study on the anticancer activity of coumarin derivatives by molecular modeling. Chem Biol Drug Des 2011; 78:651.
14. Kostova I, Bhatia S, Grigorov P, Balkansky S, Parmar VS, Prasad AK, Saso L. Coumarins as antioxidants. Curr Med Chem 2001; 18:3929.
15. Piazzi L, Cavalli A, Colizzi F, Belluti F, Bartolini M, Mancini F, et al. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett 2008; 18:423.
16. (a) Schalk I, Ehret-Sabatier L, Le Feuvre Y, Bon S, Massoulie J, Goeldner M. 6-Coumarin diazonium salt: a specific affinity label of the Torpedo acetylcholinesterase peripheral site. Mol Pharmcol 1995; 48:1063. (b) Radic´ Z, Taylor P. The influence of peripheral site ligands on the reaction of symmetric and chiral organophosphates with wildtype and mutant acetylcholinesterases. Chem Biol Interact 1999; 119–120:111. (c) Radic´ Z, Taylor P. Peripheral site ligands accelerate inhibition of acetylcholinesterase by neutral organophosphates. J Appl Toxicol 2001; 21:S13. (d) Fallarero A, Oinonen P, Gupta S, Blom P, Galkin A, Mohan CG, Vuorela PM. Inhibition of acetylcholinesterase by coumarins: The case of coumarin 106. Pharmacol Res 2008; 58:215.
17. Kontogiorgis CA, Xu Y, Hadjipavlou-Litina D, Luo Y. Coumarin derivatives protection against ROS production in cellular models of Aβ toxicities. Free Radic Res 2007; 41:1168.
18. Huang L, Su T, Shan W, Luo Z, Sun Y, He F, Li X. Inhibition of cholinesterase activity and amyloid aggregation by berberine-phenyl-benzoheterocyclic and tacrine-phenyl-benzoheterocyclic hybrids. Bioorg Med Chem 2012; 20:3038–3048.
19. Fernandez-Bachiller MI, Villarroya M, Perez C, Garcı AG, Gonzalez-Munoz G C, Rodrıguez-Franco MI, Conde S, Lopez M G. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer’s disease, with neuroprotective, cholinergic, antioxidant, and copper complexing properties. J Med Chem 2010; 53:4927–4937.
20. (a) Alipour M, Khoobi M, moradi M, Nadri H, Homayouni Moghadam F, Emami S, et al. Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives. Eur J Med Chem 2014; 82:536–544. (b) Ghanei-Nasab S, Khoobi M, Hadizadeh F, Marjani A, Moradi A, Nadri H, et al. Synthesis and anticholinesterase activity of coumarin-3-carboxamides bearing tryptamine moiety. Eur J Med Chem 2016; 121:40–46. (c) Asadipour A, Alipour M, Jafari M, Khoobi M, Emami S, Nadri H, et al. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur J Med Chem 2013; 70:623–630. (d) Razavi SF, Khoobi M, Nadri H, Sakhteman A, Moradi A, Emami S, et al. Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors. Eur J Med Chem 2013; 64:252–259. (e) Alipour M, Khoobi M, Foroumadi, Nadri H, Moradi A, Sakhteman A, et al. Novel coumarin derivatives bearing N-benzyl pyridinium moiety: Potent and dual binding site acetylcholinesterase inhibitors. Bioorg Med Chem 2012; 20: 7214–7222.
21. Trott O, Olson A. J autoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31:455–461.
22. Sanner MF. Python: a programming language for software integration and development. J Mol Graph Model 1999; 17:57–61.
23. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform 2011; 3:33.
24. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605–1612.
25. Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7:88–95.
26. Xie SS, Wang XB, Li JY, Yang L, Kong LY. Design, synthesis and evaluation of novel tacrine–coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease. Eur J Med Chem 2013; 64:540–553.
27. Rajesh H, Vekariya HD. Patel recent advances in the synthesis of coumarin derivatives via knoevenagel condensation: a review. Synth Commun 2014; 0:1–33.
28. Kathuria A, Priya N, Chand K, Singh P, Gupta A, Jalal S, et al. Substrate specificity of acetoxy derivatives of coumarins and quinolones towards Calreticulin mediated transacetylation: Investigations on antiplatelet function. Bioorg Med Chem 2012; 20:1624–1638.